Omniose

Executive Summary

Omniose is an early-stage biotechnology company headquartered in Cambridge, MA, focused on expanding the range of polysaccharide conjugate vaccines using its proprietary bioconjugation platform. Founded in 2021, the company aims to address serious bacterial threats that are currently underserved by existing vaccines. Its core technology leverages engineered cells that simultaneously produce both the polysaccharide antigen and the carrier protein, enabling efficient and scalable production of bioconjugate vaccines. This approach has the potential to target a broader array of bacterial pathogens compared to traditional chemical conjugation methods, which are often complex and costly. Omniose is currently in the preclinical stage, working to advance its lead candidates toward investigational new drug (IND) filing. The company's platform could significantly impact global health by providing more accessible and affordable vaccines against diseases such as bacterial pneumonia, sepsis, and hospital-acquired infections. Given its early stage, Omniose faces typical risks associated with preclinical development, including scientific validation, manufacturing scalability, and funding needs. However, the bioconjugate vaccine space has garnered increasing interest, with precedents like Pfizer's Prevnar demonstrating commercial viability. Omniose's differentiation lies in its proprietary platform, which may enable faster development and broader coverage. The company's progress over the next 12–18 months will be critical, with potential catalysts including preclinical proof-of-concept data, strategic partnerships, or a Series A financing round. Success in these milestones could position Omniose as a key player in the next generation of bacterial vaccines.

Upcoming Catalysts (preview)

• Q3 2026Preclinical in vivo efficacy data for lead vaccine candidate60% success
• Q4 2026Series A financing round closing70% success
• TBDAnnouncement of partnership or licensing deal with larger pharma40% success